Agenus Extends Cash Runway In GSK Partnership Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
You may also be interested in...
GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot
Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.